AtriCure (AtriCure) GF Value : $62.33 (As of Apr. 25, 2024)

View and export this data going back to 2005. Start your Free Trial

What is AtriCure GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-04-25), AtriCure's share price is $22.61. AtriCure's GF Value is $62.33. Therefore, AtriCure's Price-to-GF-Value for today is 0.36.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes AtriCure is Significantly Undervalued.

AtriCure (NAS:ATRC) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

AtriCure's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	22.61	/	62.33
	=	0.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AtriCure GF Value Related Terms

Thank you for viewing the detailed overview of AtriCure's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

AtriCure (AtriCure) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AtriCure Inc (NAS:ATRC) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

7555 Innovation Way, Mason, OH, USA, 45040

Website

https://www.atricure.com

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.

Executives

Karl S. Dahlquist	officer: Chief Legal Officer	7555 INNOVATION WAY, MASON OH 45040
Karen Prange	director	1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316
Maggie Yuen	director	ONE PENUMBRA PLACE, ALAMEDA CA 94502
Vinayak Doraiswamy	officer: Chief Scientific Officer	7555 INNOVATION WAY, MASON OH 45040
Deborah Lee Yount	officer: Chief Human Resources Officer	7555 INNOVATION WAY, MASON OH 45040
Tonya Austin	officer: Chief Human Resources Officer	7555 INNOVATION WAY, MASON OH 45040
Angela L Wirick	officer: Chief Financial Officer	7555 INNOVATION WAY, MASON OH 45040
Mark A Collar	director	382 BISHOPBRIDGE DR, CINCINNATI OH 45255
Regina E Groves	director	5751 COPLEY DRIVE, SAN DIEGO CA 92111
Douglas J Seith	officer: SVP of Sales and Marketing	7555 INNOVATION WAY, MASON OH 45040
Salvatore Privitera	officer: VP; Product Development	7555 INNOVATION WAY, MASON OH 45040
Justin J Noznesky	officer: SVP, Mktg & Business Develop	7555 INNOVATION WAY, MASON OH 45040
Deborah H Telman	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Scott William Drake	director	9965 FEDERAL DRIVE, COLORADO SPRINGS CO 80921
Sven Wehrwein	director